The team analyzed twenty-three formalin-fixed, paraffin-embedded lung tissue samples from nineteen patients who died with COVID-19-associated diffuse alveolar damage, alongside four control lungs with normal morphology. The samples spanned the two canonical histological stages of the disease: seven cases of acute diffuse alveolar damage, marked by early epithelial lesions, interstitial inflammation and edema, and twelve cases of proliferative damage, characterized by pneumocyte hyperplasia and fibroblast proliferation. Using the 10x Genomics Visium platform, which captures gene expression on a slide dotted with thousands of barcoded spots each covering roughly one to ten cells, the researchers profiled a total of 91,068 tissue spots after quality control. To identify which cell types occupied each spot, they used the cell2location algorithm to deconvolve the spatial data against the integrated Human Lung Cell Atlas, a single-cell reference containing hundreds of thousands of lung cells, resolving forty-five distinct cell populations across four major lineages: epithelial, endothelial, immune and stromal.

The resulting cellular census revealed a striking, directional remodeling of the dying lung. In healthy tissue, endothelial cells are the most abundant lineage, and capillary cell types alone account for roughly thirty percent of all lung cells. As diffuse alveolar damage progressed from acute to proliferative stages, the researchers documented a progressive loss of endothelial populations, including aerocyte capillary, arterial, general capillary and venous pulmonary endothelial cells, a finding that aligns with growing evidence linking SARS-CoV-2 infection to endothelial dysfunction. The only shift that reached statistical credibility by the Bayesian compositional analysis scCODA, at a false discovery rate below 0.05, was the reduction of endothelial cells in proliferative disease compared with controls, but the trend was consistent across the entire endothelial compartment. On the epithelial side, alveolar type 1 cells, which normally form the thin blood-gas barrier, were significantly depleted in proliferative damage, while alveolar type 2 cells, the progenitors that repair injured alveoli, expanded. This inverse relationship captures the essence of the pathology: the fragile gas-exchange surface is destroyed while the repair machinery struggles to compensate.

The immune landscape shifted in parallel. Alveolar macrophages, CCL3-positive macrophages and monocyte-derived macrophages were significantly overrepresented in proliferative disease, and interstitial perivascular macrophages rose steadily across stages. In contrast, the lymphoid compartment contracted: CD4 and CD8 T cells declined, and natural killer cells showed a significant drop from control and acute samples to proliferative cases. Because natural killer cells are innate effectors central to the response against acute viral infection, their progressive disappearance reinforces prior reports tying NK cell dysfunction to COVID-19 severity and lethality. Among stromal cells, the most dramatic change belonged to peribronchial fibroblasts, which increased from control to acute damage and then skyrocketed in the proliferative stage. Other fibroblast subsets behaved differently: subpleural and adventitial fibroblasts expanded, while alveolar fibroblasts and pericytes, which contribute to tissue homeostasis, decreased. The specificity of the peribronchial fibroblast expansion would prove to be one of the study’s most consequential observations.

Beyond counting cells, the study interrogated how they were arranged. Non-negative matrix factorization of cell-type abundance estimates identified eight recurring modules of co-occurring cell types, or spatial compartments. In normal lung, these corresponded to physiological microenvironments, such as a large immune-endothelial compartment, an epithelial compartment, and a smooth-muscle and fibroblast compartment in which peribronchial fibroblasts resided in isolation. With acute damage, this architecture fractured: proliferating alveolar type 2 cells were recruited into the epithelial compartment, macrophage subtypes and type-2 dendritic cells formed a new immune cluster, and plasma cells appeared as an isolated population. In proliferative damage, the compartmentalization deepened further, with mature lymphatic endothelial cells emerging as a unique niche. A graph-based comparison method called GraphCompass quantified these architectural shifts, showing that peribronchial fibroblasts, alveolar fibroblasts, alveolar type 2 cells, aerocyte capillary endothelial cells and monocyte-derived macrophages underwent the most pronounced spatial remodeling. Filtration curve analysis confirmed the picture: peribronchial fibroblasts and alveolar type 2 cells clustered ever more tightly in proliferative disease, while capillary endothelial cells became fragmented and dispersed as they were depleted.

The researchers then turned to intercellular communication, using spatially weighted ligand-receptor interaction scores decomposed into three communication signatures by non-negative matrix factorization. The third signature best discriminated diseased from healthy lung and was significantly enriched for interactions belonging to the transforming growth factor beta pathway, the master driver of fibrosis, while being depleted for the epidermal growth factor receptor pathway. The top ligand-receptor pairs defining this signature included TIMP1 binding CD63, an interaction known to promote lung fibrosis through the TGF-beta1/SMAD3 axis; amyloid precursor protein binding CD74, implicated in capillary barrier defense during infection; CD99 with CD81, both regulators of lymphocyte activity; and lumican binding integrin beta 1, linked to extracellular matrix remodeling. Additional prominent interactions involved S100A8 and S100A9 binding their receptors, known to activate macrophages in COVID-19, SPARC binding endoglin, and vimentin binding CD44, an attachment factor that facilitates SARS-CoV-2 entry into endothelial cells. The three most frequent receptors in the diseased-lung interactome were CD44, integrin beta 1, which associates with ACE2 to mediate viral entry, and LRP1, previously enriched in mortal and long COVID-19 cases.

Inside the cells, transcription factor activity analysis using the decoupleR framework and the CollecTRI regulatory network revealed the same profibrotic logic operating at the level of gene regulation. Proliferative damage was characterized by upregulation of SMAD3, the key mediator of TGF-beta signaling that drives extracellular matrix production and scar formation, coupled with downregulation of SMAD7, the pathway’s natural antagonist. This SMAD3-high, SMAD7-low axis proved remarkably disease-specific: when the researchers validated their findings against the extended Human Lung Cell Atlas, spanning more than 1.4 million cells from healthy lungs, non-COVID-19 pneumonia, idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease, SMAD3 ranked as the second most upregulated and SMAD7 the second most downregulated transcription factor in COVID-19 relative to healthy lung, a pattern absent in the other conditions. Spatially, peribronchial fibroblast abundance co-clustered with SMAD3 activity and segregated from SMAD7 activity, and the TIMP1-CD63 interaction showed the strongest spatial co-localization of any ligand-receptor pair, particularly within proliferative lesions. A predictive model linking communication and transcriptional signals to cell abundance explained a mean of 21 percent of the variance in cell-type composition, with transcription factor activity contributing roughly twice as much as ligand-receptor interactions.

By inferring a putative causal signaling network within peribronchial fibroblasts, the team traced a pathway with direct therapeutic implications. Activation of the integrin ITGB1 receptor unleashed downstream kinases including ILK, AKT1, MAP2K4 and MAPK14, ultimately activating SMAD3, MYB and BRCA1 while repressing SMAD7 and CIITA, the latter repression potentially unleashing collagen expression after injury. Because MAPK14 inhibitors such as ralimetinib and ARRY-797 have shown antiviral activity against SARS-CoV-2, and because the approved antifibrotic drugs pirfenidone, which inhibits TGF-beta, and nintedanib, which blocks multiple kinases, are already used in idiopathic pulmonary fibrosis, the authors argue that their spatially resolved pathway map points to concrete candidates for repurposing against COVID-19-associated fibrosis. They also flag NLRP3 inflammasome inhibitors for the hyperactivated myeloid compartment, MYB and the S100A9-CD68 interaction as myeloid targets, and even speculate that amyloid precursor protein interactions in the injured lung might connect pulmonary damage to the cognitive impairment seen after COVID-19, suggesting dual-action strategies such as lysophosphatidic acid receptor inhibitors.

The study closed with two forward-looking analyses. A graph neural network approach showed that natural killer cells in healthy lung depend on multiple neighboring cell types, including CD8 T cells, aerocyte capillary endothelial cells and alveolar type 1 cells, dependencies that vanished entirely in diseased tissue, while CD4 T cells became prominent communication receivers in damaged lung. And a spatio-temporal trajectory reconstruction using the stLearn pseudo-time-space algorithm captured alveolar type 2 cells actively transitioning into type 1 cells in proliferative lesions, with one trajectory clade expressing the late maturation marker CAV1, evidence that regeneration programs do engage even in fatally injured lungs, though too late or too incompletely to restore gas exchange. The authors caution that their samples are post-mortem and may reflect downstream consequences of prolonged illness, and that longitudinal samples from the same patients were unavailable to confirm temporal progression. Still, by benchmarking their findings against non-COVID-19 diffuse alveolar damage and idiopathic pulmonary fibrosis, and showing that peribronchial fibroblasts form unique spatial niches only in COVID-19, the work establishes a spatially informed blueprint of fatal COVID-19 lung pathology, and a proof of principle for spatial transcriptomics as a bridge between molecular data and personalized medicine.

Subject of Research: Spatial transcriptomic mapping of cellular and molecular changes in fatal COVID-19 lung diffuse alveolar damage

Article Title: Spatial transcriptomics unveils the in situ cellular and molecular hallmarks of the lung in fatal COVID-19

Article References: Garcia-Prieto, C. A., Musulen, E., Grases, D., Davalos, V., Ferrer, G., Pérez-Miés, B., Caniego-Casas, T., Palacios, J., Saenz-Sardà, X., Englund, E., Porta, E., & Esteller, M. (2026). Spatial transcriptomics unveils the in situ cellular and molecular hallmarks of the lung in fatal COVID-19. Nature Communications, 17(1), Article 10405. https://doi.org/10.1038/s41467-026-78188-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78188-3

Keywords: spatial transcriptomics, COVID-19, SARS-CoV-2, diffuse alveolar damage, lung fibrosis, TGF-beta, SMAD3, peribronchial fibroblasts, endothelial cells, natural killer cells, alveolar regeneration, cell-cell communication

The team, led by Shilong Liu and senior author Zhenhua Zhu of the First Affiliated Hospital of Hunan University of Chinese Medicine, began by mining publicly available single-cell RNA sequencing datasets from the Gene Expression Omnibus. After quality control and integration, they analyzed 41 CRSwNP samples and 7 healthy controls, resolving the nasal tissue microenvironment into 13 major cell populations. They then zoomed in on the two compartments most directly responsible for tissue architecture: the epithelium, which forms the mucosal barrier, and the fibroblasts of the underlying lamina propria, which manufacture the extracellular matrix. Epithelial cells resolved into 13 subpopulations and fibroblasts into 8, each defined by distinct functional states.

The compositional shifts they observed were striking and asymmetric. In the epithelial compartment, six of the thirteen subpopulations changed significantly in disease. Inflammatory CXCL8-positive cells and MUC5AC-positive goblet cells expanded, while homeostatic FOXJ1-positive ciliated cells, the workhorses of mucociliary clearance, shrank. Basal-like populations marked by KRT15 and COL17A1 grew, signaling a tissue locked into a perpetual injury-repair mode. Fibroblasts shifted more modestly, but the direction was telling: inflammatory CCL2-positive fibroblasts increased while APOD-positive homeostatic fibroblasts declined. The epithelium, in other words, tilted toward inflammation and aberrant secretion, while the stroma edged toward activation.

Differential expression and gene set enrichment analysis deepened the story. Diseased epithelial cells upregulated genes tied to injury responses and remodeling, including SERPINB4, KRT13, MMP7, and VIM, while losing genes that maintain barrier function and ciliary differentiation such as SCGB1A1, FOXJ1, and MUC5B. Enriched pathways included epithelial-mesenchymal transition, hypoxia, inflammatory response, and TGF-beta and WNT signaling. Fibroblasts showed a complementary profile: POSTN, COL1A2, SERPINE1, and CCL2 rose, while homeostatic genes like PI16 and MFAP4 fell, with collagen metabolism and TGF-beta production prominently enriched. Shared hub genes such as IL6 and SERPINE1 appeared in both cell types, hinting at a common inflammatory and matrix-remodeling program.

Pseudotime analysis using Monocle3 and CytoTRACE2 then reconstructed how these states emerge. Epithelial cells appeared to branch from a secretory starting point toward ciliated, mucous, and injury-repair fates, with homeostatic genes like EPCAM and CDH1 declining along the trajectory while KRT15, COL17A1, and the EMT-associated transcription factor SNAI2 increased. Fibroblasts progressed from quiescent CFD- and APOD-expressing states toward activated, contractile phenotypes marked by TAGLN, POSTN, and MYL9, with collagen genes COL1A1 and COL1A2 peaking in mid-to-late pseudotime. The picture is one of gradual, coordinated drift away from tissue homeostasis rather than an abrupt switch.

The most consequential findings came from CellChat, a computational framework that infers ligand-receptor communication between cell populations. In CRSwNP, the overall communication network grew denser and stronger, with two modules standing out. The COLLAGEN module, built on pairs such as COL1A1 and COL1A2 binding CD44, SDC4, and integrins, flowed predominantly from activated fibroblast subpopulations toward specific epithelial subsets. The TGF-beta module, involving TGFB1 binding TGFBR1/TGFBR2 and ACVR1, was more bidirectional, with epithelial and fibroblast compartments signaling reciprocally. Extending the analysis to myeloid cells, the team found that TGFB1 transcripts concentrated in a GPNMB-expressing macrophage state, marked by SPP1, TREM2, and MMP9, that was significantly expanded in polyps, echoing scar-associated macrophages described in fibrotic liver and other tissues.

Crucially, the computational predictions held up at the protein level in human tissue. Examining nasal polyps from three patients and control mucosa from three individuals undergoing septal surgery, the researchers used Masson’s trichrome staining and tyramide signal-amplified immunofluorescence. Polyps showed denser subepithelial collagen deposition, stronger COL1A1 and alpha-SMA signals in the lamina propria, nuclear accumulation of phosphorylated Smad3 in epithelial cells, weakened E-cadherin, and increased N-cadherin and periostin, all statistically significant. One particularly revealing observation concerned architecture rather than abundance: in healthy mucosa, COL1A1 and periostin formed a compact, continuous band beneath the epithelium, but in polyps this band became loose and discontinuous, with matrix proteins diffusing into the lamina propria. Remodeling in CRSwNP, the data suggest, involves not just more matrix but disorganized matrix.

To test causality in a living system, the team established a CRSwNP-like mouse model using intranasal ovalbumin challenge combined with Staphylococcus aureus enterotoxin B, a superantigen long implicated in polyp formation. Over roughly four months, model mice developed thickened respiratory epithelium, polypoid protrusions, inflammatory infiltration, and significantly increased subepithelial collagen by Sirius Red staining under polarized light. Immunofluorescence mirrored the human findings: alpha-SMA-positive cells accumulated with COL1A1 deposition, epithelial E-cadherin fell, nuclear p-Smad3 rose, and N-cadherin and periostin increased. Western blotting confirmed elevated COL1A1, POSTN, N-cadherin, alpha-SMA, and an increased p-Smad3 to total Smad3 ratio.

The therapeutic implications emerged when the researchers treated model mice with dexamethasone, the corticosteroid that remains first-line therapy for CRSwNP. The drug partially reversed the remodeling phenotype: alpha-SMA and E-cadherin returned to levels statistically indistinguishable from controls, while COL1A1, POSTN, and N-cadherin declined but stayed above baseline. The p-Smad3/Smad3 ratio showed only a non-significant downward trend. This partial response is mechanistically coherent, since the glucocorticoid receptor is known to directly inhibit the transcriptional activation function of Smad3, but it also carries a sobering message: broad anti-inflammatory treatment alone may not fully reverse established structural remodeling, and pathway-targeted anti-fibrotic strategies deserve exploration.

The authors are careful about the limits of their work. CellChat and pseudotime analyses are computational inferences that nominate candidate signaling axes rather than prove physical ligand-receptor engagement, and no knockdown, pathway blockade, or co-culture experiments were performed. The two public cohorts differ in ethnicity and inflammatory endotype, one skewed toward Type 2 inflammation and the other toward IL-1beta-driven myeloid inflammation, and eosinophils, classic sources of TGF-beta1 in polyps, were too sparsely captured for subcluster analysis. Yet the reproducible detection of the same epithelial-fibroblast TGF-beta/Smad axis across cohorts differing in platform, ancestry, and sampling site argues that it is a shared feature of polyp remodeling rather than a cohort-specific artifact. If future spatially resolved and functional studies confirm this circuit, the collagen and TGF-beta dialogue between epithelium and stroma could become a tractable target for therapies aimed not just at shrinking polyps, but at preventing the scarring that makes them return.

Subject of Research: TGF-beta/Smad-mediated epithelial-fibroblast remodeling and collagen deposition in chronic rhinosinusitis with nasal polyps

Article Title: TGF‐β/Smad‐Associated Epithelial–Fibroblast Remodeling Underlies Collagen Deposition in Chronic Rhinosinusitis With Nasal Polyps

Article References: Liu, S., Xie, P., Deng, H., & Zhu, Z. (2026). TGF‐β/Smad‐Associated Epithelial–Fibroblast Remodeling Underlies Collagen Deposition in Chronic Rhinosinusitis With Nasal Polyps. Immunity, Inflammation and Disease, 14(10), Article e70532. https://doi.org/10.1002/iid3.70532

Image Credits: AI Generated

DOI: 10.1002/iid3.70532

Keywords: chronic rhinosinusitis, nasal polyps, TGF-beta, Smad3, fibroblasts, epithelial-mesenchymal transition, collagen deposition, single-cell RNA sequencing, CellChat, macrophages, dexamethasone, tissue remodeling

The kidney’s filtering units, the glomeruli, depend on a specialized layer of cells called podocytes. These cells wrap around the glomerular capillaries with interdigitating foot processes, forming slit diaphragms that act as the final, exquisitely selective barrier preventing albumin and other precious proteins from leaking into the urine. Podocytes are terminally differentiated epithelial cells; once damaged, they do not readily regenerate. One of the most consequential forms of podocyte injury is a process known as epithelial-to-mesenchymal transition, or EMT, in which these highly specialized epithelial cells lose their characteristic architecture and adhesion molecules and begin expressing mesenchymal markers such as N-cadherin, vimentin, and fibronectin. The transformed cells become motile, detach from the glomerular basement membrane, and contribute to the fibrotic scarring that progressively chokes off renal function. Prior work has implicated the TGF-beta signaling pathway, and its intracellular mediator SMAD3, as a central driver of this transition in the diabetic kidney.

The Harbin team began not in the laboratory but in the data. By integrating transcriptomic datasets from public repositories, they searched for RNA-binding proteins that were aberrantly expressed in diabetic kidney tissue, and PTBP3 emerged as a standout candidate. Polypyrimidine tract-binding protein 3 is a member of a family of proteins that bind specific sequence motifs in messenger RNA molecules, influencing their stability, translation, and alternative splicing. PTBP3 has attracted increasing attention in oncology research, where it has been shown to promote epithelial-to-mesenchymal transition and metastasis in lung adenocarcinoma, drive growth in colorectal and gastric cancers, and modulate immune escape in gallbladder cancer. Its role in kidney disease, however, had remained essentially unexplored, making the new findings a notable expansion of the protein’s known biological territory.

To confirm that the computational signal reflected real biology, the researchers turned to animal and cell models. In mice made diabetic by injection of streptozotocin, a compound that selectively destroys insulin-producing beta cells and reliably induces hyperglycemia, PTBP3 levels rose in kidney tissue. The same elevation appeared in podocytes grown in culture and exposed to high glucose concentrations, the standard in vitro model of diabetic cellular stress. These convergent observations, in vivo and in vitro, established that PTBP3 upregulation is a reproducible feature of the diabetic kidney environment rather than an artifact of any single experimental system, and positioned the protein as a plausible participant in disease pathogenesis.

The decisive experiment came next. The team knocked down PTBP3 in diabetic mice and monitored the classic functional readouts of kidney injury. The results were striking: 24-hour urinary protein excretion, a direct measure of the damaged filtration barrier, was significantly reduced in the knockdown animals. Serum creatinine and blood urea nitrogen, the two workhorse clinical markers of declining kidney clearance, were also substantially attenuated compared with diabetic controls. In other words, removing this single RNA-binding protein preserved measurable kidney function in the face of ongoing diabetes.

Histological analysis told a matching structural story. Under the microscope, the kidneys of diabetic mice typically show glomerular hypertrophy, expansion of the mesangial matrix that crowds the filtering tuft, and the deposition of collagen-rich fibrotic tissue. In the PTBP3 knockdown animals, all of these pathological features were ameliorated. Renal fibrosis was reduced, and the glomerular architecture was better preserved. The researchers further demonstrated that PTBP3 silencing inhibited the epithelial-to-mesenchymal transition of podocytes in the diabetic mice, an effect visible at the molecular level as restored expression of E-cadherin, the epithelial adhesion molecule that anchors podocytes in place, alongside reduced expression of the mesenchymal markers N-cadherin, vimentin, and fibronectin. Cultured podocytes subjected to high glucose showed the same pattern, reinforcing the consistency of the mechanism across model systems.

The mechanistic core of the paper lies in how PTBP3 exerts these effects, and here the authors provide a satisfying molecular explanation centered on SMAD3, the transcriptional mediator of TGF-beta signaling that has long been associated with fibrotic disease. Using dual-luciferase reporter assays and RNA immunoprecipitation, the team showed that PTBP3 physically interacts with the 3-prime untranslated region of SMAD3 messenger RNA. This interaction stabilizes the transcript, increasing the total amount of SMAD3 protein produced and, consequently, the levels of its phosphorylated, active form. In effect, PTBP3 acts as a post-transcriptional amplifier: by protecting SMAD3 mRNA from degradation, it boosts the signaling output of the TGF-beta pathway, which in turn drives podocytes toward the mesenchymal, fibrosis-promoting state. When PTBP3 is removed, SMAD3 expression falls, phosphorylation declines, and the EMT program loses its principal engine.

This finding places PTBP3 within a growing map of post-transcriptional regulation in diabetic kidney disease. The SMAD3 axis itself is well established: genetic deletion of Smad3 has previously been shown to prevent renal fibrosis and inflammation in models of type 2 diabetic nephropathy, and multiple microRNAs and circular RNAs have been described that modulate SMAD3 expression in mesangial cells and podocytes. What the new study adds is a specific RNA-binding protein that tunes the pathway at the level of mRNA stability, a layer of control that has been harder to drug than receptors or kinases but is increasingly recognized as a rich source of therapeutic targets. The parallel with cancer biology is also instructive, since PTBP3 has been repeatedly linked to TGF-beta-driven EMT in tumors, suggesting that the protein operates a conserved program of epithelial plasticity that the diabetic kidney co-opts for pathological remodeling.

The clinical implications, while still distant, are worth considering carefully. Diabetic nephropathy affects an enormous fraction of the growing global population with diabetes, and a substantial share of patients progress to dialysis or transplantation despite current best care. A target that acts upstream of SMAD3, and that demonstrably reduces proteinuria and preserves histology in a diabetic mouse model, represents the kind of mechanistic entry point that could eventually yield new drug classes, whether antisense oligonucleotides, small molecules that disrupt the PTBP3-SMAD3 mRNA interaction, or delivery strategies aimed specifically at podocytes. The authors note that PTBP3 knockdown ameliorated renal fibrosis and preserved renal function, underscoring the therapeutic potential of targeting podocyte epithelial-mesenchymal transition in diabetic nephropathy. At the same time, the usual caveats apply: mouse models of streptozotocin-induced diabetes capture only part of human diabetic kidney disease, and PTBP3’s roles in other tissues, including its documented effects in hematopoietic and endothelial biology, will need to be weighed against any systemic intervention.

For now, the study stands as a clear demonstration that the fate of the kidney’s filtration barrier can be steered by a single post-transcriptional regulator. By tracing a line from public transcriptomic data through diabetic mice and glucose-stressed podocytes down to a specific interaction between an RNA-binding protein and the untranslated region of a fibrotic transcription factor, the Harbin researchers have connected a molecular mechanism to clinically meaningful outcomes: less protein in the urine, lower creatinine, less scarring, better-preserved glomeruli. If those findings can be replicated in additional models and extended toward human tissue validation, PTBP3 may join the short list of molecules that clinicians watch as potential handles on one of diabetes’ most feared complications. The work was supported by the Basic Scientific Research Business Expenses Project of Colleges and Universities in Heilongjiang Province, and all animal experiments were approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University.

Subject of Research: The role of the RNA-binding protein PTBP3 in Smad3-dependent podocyte injury and fibrosis in diabetic nephropathy

Article Title: PTBP3 promotes diabetic nephropathy via Smad3-dependent podocyte-mesenchymal transition

Article References: Li, Y., Fu, Y., Wang, X., Ma, X., Cong, G., & Sui, M. (2026). PTBP3 promotes diabetic nephropathy via Smad3-dependent podocyte-mesenchymal transition. Molecular Biology Reports, 53(1), Article 1628. https://doi.org/10.1007/s11033-026-12788-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12788-6

Keywords: diabetic nephropathy, PTBP3, podocytes, SMAD3, epithelial-mesenchymal transition, renal fibrosis, RNA-binding proteins, TGF-beta signaling, chronic kidney disease, proteinuria, mRNA stability, kidney disease

The research, led by Xiao Yang and Xiaoqing Wang, who share first authorship, together with senior authors Qingchen Wu and Lanxiang Wu at Chongqing Medical University, took a deliberately multimodal approach. Rather than relying on a single technology, the team integrated single-cell RNA sequencing, which profiles gene expression in thousands of individual cells, with single-cell spatial transcriptomic analyses of NSCLC samples. This combination allowed them not only to catalog the cellular inhabitants of the tumor microenvironment but also to map precisely where those cells sit relative to one another within intact tissue, a critical dimension because the geometry of a tumor often determines how its cells communicate.

The central motivation was a question that has lingered in the field for years: the tumor microenvironment of NSCLC is known to differ across oncogenic driver mutations, but whether specific stromal states are directly shaped by those mutations, and how such states influence tumor progression and therapy response, has remained inadequately understood. Most studies of cancer-associated fibroblasts, the spindle-shaped stromal cells that infiltrate and remodel tumors, have treated them as a single broad category or divided them along generic lines of activation. The Chongqing team instead asked whether the driver mutation carried by the tumor cells leaves a fingerprint on the fibroblasts surrounding them.

It does. By computationally dissecting the single-cell data, the researchers identified a fibroblast subpopulation that is markedly enriched in EGFR-mutant NSCLC compared with tumors driven by other mutations. They named this subtype Fib_COL16A1, after its signature gene product, collagen type XVI alpha 1 chain (COL16A1), a component of the extracellular matrix that anchors basement membranes to surrounding connective tissue. The finding was not a fleeting transcriptional quirk. Regulatory network inference pointed to SMAD3, a transcription factor downstream of the TGF-beta signaling pathway, as the molecular maintainer of the Fib_COL16A1 identity, suggesting that a defined transcriptional program, rather than random stochastic variation, keeps these cells in their specialized state.

Perhaps most striking was the evolutionary conservation of the subtype. When the team examined murine NSCLC models, they found a corresponding population, Fib_Col16a1, mirroring the human cells. This cross-species consistency matters enormously for translational research, because it means the mouse models routinely used to preclinical-test new therapies actually reproduce the stromal niche the human study identified, giving investigators a legitimate experimental system in which to interrogate and attack it.

The clinical stakes became clear when the researchers examined survival data. The abundance of Fib_COL16A1 cells functioned as an independent prognostic marker for poor survival, meaning that even after accounting for other established clinical and pathological variables, patients whose tumors harbored more of these fibroblasts fared worse. That statistical independence elevates the subtype from an interesting correlation to a potential biomarker, one that could eventually help stratify patients with EGFR-mutant lung adenocarcinoma at diagnosis.

Spatial transcriptomics then revealed where these cells operate. Fib_COL16A1 cells were found to colocalize with two distinct partners: tumor cells themselves and CD8-positive T cells, the cytotoxic immune cells that, in principle, should recognize and kill cancer cells. This dual positioning hinted at a dual function, and functional experiments in vitro and in vivo confirmed it. In co-culture and animal models, Fib_COL16A1 cells enhanced the proliferation of EGFR-mutant tumor cells, directly feeding tumor growth. At the same time, in the niches they shared with CD8-positive T cells, they promoted a state of T-cell exhaustion, the dysfunctional, hyporesponsive condition that renders cytotoxic lymphocytes incapable of mounting an effective anti-tumor attack.

The mechanistic thread connecting these effects is a signaling axis between COL16A1, the collagen secreted by the fibroblasts, and integrin beta 1 (ITGB1), a receptor on the surface of responding cells. Integrins are the workhorse adhesion and signaling receptors of the extracellular matrix, and the study demonstrated that the COL16A1-integrin beta 1 axis is the conduit through which Fib_COL16A1 cells exert their pro-tumor influence, transmitting proliferative signals to tumor cells and exhaustion-inducing signals to T cells. Chromatin immunoprecipitation and other molecular assays in the study’s toolkit helped pin down the regulatory architecture, from SMAD3’s maintenance of the fibroblast state to the downstream consequences of axis engagement.

The therapeutic implications are the most immediately exciting part of the work. When the researchers therapeutically targeted the COL16A1-integrin beta 1 axis, two things happened: tumor progression was impeded, and the tumors became more sensitive to both osimertinib, the third-generation EGFR tyrosine kinase inhibitor that is the standard of care in EGFR-mutant NSCLC, and pembrolizumab, the PD-1 immune checkpoint antibody that has historically delivered disappointing results in this molecular subgroup. In other words, breaking the stromal signaling axis did not just slow the tumor directly; it re-sensitized the disease to the two most important drugs already in the clinic, suggesting a rational triple-combination strategy in which stromal targeting unlocks the efficacy of existing targeted and immunotherapies.

The study, registered with the Chinese Clinical Trial Registry and approved by the ethics committees of Chongqing Medical University, reframes how scientists think about driver mutations in cancer. An EGFR mutation has conventionally been viewed as a cell-intrinsic engine of tumor growth, a lesion that makes cancer cells proliferate and survive. This work adds a second, ecosystem-level dimension: the mutation appears to recruit or reprogram the stroma into a supportive architecture, complete with dedicated fibroblast niches that simultaneously nourish the tumor and wall off immune attack. If the COL16A1-integrin beta 1 axis can be safely drugged, the mutation-specific stromal-tumor-immune network described by Yang, Wang, Wu and colleagues may become one of the first examples of a driver-mutation-shaped microenvironment converted from an obstacle into a therapeutic target, a prospect that could reshape treatment paradigms for the many patients whose EGFR-mutant lung cancers still outpace current therapies.

Subject of Research: A COL16A1-expressing fibroblast subtype and its spatial niches in EGFR-mutant non-small cell lung cancer

Article Title: Multimodal analysis identifies a fibroblast subtype enriched in EGFR-mutant NSCLC and its spatial niches

Article References: Yang, X., Wang, X., Zhang, M., Du, R., Lei, T., Wu, Q., & Wu, L. (2026). Multimodal analysis identifies a fibroblast subtype enriched in EGFR-mutant NSCLC and its spatial niches. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03842-z

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03842-z

Keywords: EGFR-mutant NSCLC, cancer-associated fibroblasts, COL16A1, integrin beta 1, spatial transcriptomics, single-cell RNA sequencing, tumor microenvironment, CD8 T-cell exhaustion, osimertinib, pembrolizumab, SMAD3, lung adenocarcinoma